D. A. Bereznikova

D. A. Bereznikova

Auto-generated profile, based on publicly available information

D. A. Bereznikova

Kursk State Medical University, Ministry of Health of Russia; G.E. Ostroverkhov Kursk Cancer Research and Clinical Center

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
DPDmitry V Petrochenko
Dmitry V Petrochenko
DBD.A. Bereznikova
D.A. Bereznikova
FPF.V. Podolsky
F.V. Podolsky
IAI.E. Alekseev
I.E. Alekseev
AKA.D. Kondrashkina
A.D. Kondrashkina
ISIrina Vasil’evna Stanoevich
Irina Vasil’evna Stanoevich
Objective. To assess the relationship between skeletal muscle index (SMI) and the frequency, nature, and severity of toxic complications in patients with locally advanced and metastatic gastric cancer during antitumor drug therapy, a study is being conducted Material and methods. The study included 100 patients diagnosed with gastric cancer who had undergone four courses of chemotherapy. Computed tomography was used for sarcopenia diagnosis. SMI was calculated as the ratio of the average skeletal muscle area at the L3 level to the square of the patient’s height. The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 scale was used to assess the severity of adverse events. Results. Correlation analysis showed a moderate, inverse, statistically significant relationship (p<0.05) between SMI before treatment and the severity of anemia and vomiting after the fourth course of chemotherapy (r=–0.302; r=–0.331). A moderate, inverse relationship (p<0.05) was observed between SMI and the severity of anemia, vomiting (r=–0.323; r=–0.397), and hypoproteinemia (r=–0.300) after four courses of chemotherapy. SMI before treatment correlated weakly (p0.05) with SMI before treatment and after four courses of chemotherapy. Conclusion. The presence of sarcopenia in patients with gastric cancer may serve as a predictor of an increase in the severity of toxicity of antitumor drug therapy. The routinely used bode mass index and body surface area during treatment are not reliable markers for predicting toxicity.

7 April 2026 in Siberian journal of oncology
Verified
Journal Article
Closed access
DBD. A. Bereznikova
D. A. Bereznikova
ISIrina Vasil’evna Stanoevich
Irina Vasil’evna Stanoevich
Objective : to analyze current approaches to the assessment of biochemical markers of skeletal muscle metabolism, to identify promising research directions in this feld, and to outline potential therapeutic strategies. Material and Methods . The literature search for the preparation of the review was conducted using the Web of Science, Scopus, MEDLINE, Cochrane Library, RSCI, and PubMed databases. A total of 146 sources were analyzed, of which 47 scientifc publications were selected. The review includes studies published between 2010 and 2025. Results . Sarcopenia in cancer patients involves four key proteolytic cascades: the ubiquitin– proteasome pathway, autophagic pathway, calpain-dependent pathway, and caspase-dependent pathway. Particular attention was given to the prognostic role of biochemical markers, including muscle-specifc E3 ligases (MuRF1, Atrogin-1), infammatory cytokines, and cystatin C. A high prognostic value of the creatinineto-cystatin C ratio was demonstrated for assessing the risk of anticancer therapy toxicity and mortality. Promising molecular targets, such as AMPK, IGF-1/AKT/mTOR, and the NF-κB, were identifed for targeted therapy. Conclusion . Sarcopenia in cancer arises from complex and molecular mechanisms, including both protein degradation and impaired muscle tissue regeneration. The use of biochemical markers and targeted interventions opens up prospects for precise, personalized medicine, enabling earlier diagnosis, accurate prognosis, and tailored treatments. Further clinical studies are required to validate biomarkers and evaluate the effectiveness of novel therapeutic strategies aimed at preventing muscle atrophy in cancer patients.